• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

What is ALS/MND?

Motor Neurone Disease (MND) is the name given to a group of diseases in which the nerve cells (neurones) that control muscles undergo degeneration and die. Amyotrophic Lateral Sclerosis (ALS), Progressive Muscular Atrophy (PMA), Progressive Bulbar Palsy (PBP), and Primary Lateral Sclerosis (PLS) are all subtypes of motor neurone disease.

MND is the widely used generic term in the United Kingdom, Australia, and parts of Europe, while ALS is used more generically in the United States, Canada, and South America.

These diseases are also sometimes known as Maladie de Charcot and are often referred to in the United States as Lou Gehrig’s Disease, after the famous baseball player who died of the disease.

How Does ALS/MND Affect the Body?

By any name, ALS/MND is characterised by progressive degeneration of the motor nerve cells in the brain and spinal cord. The motor cells (neurones) control the muscles that enable us to move around, speak, breathe, and swallow.

With no nerves to activate them, muscles gradually weaken and waste. Symptoms may include muscle weakness and paralysis, as well as impaired speaking, swallowing, and breathing. Progress is generally rapid, with an average life expectancy of between 2 and 5 years from the onset of symptoms.

Though it can affect anyone, ALS/MND is more often found in the 40 to 70 year age group.

How Common Is ALS/MND?

The impact of ALS/MND on the community is usually measured by incidence and prevalence. Incidence is the number of new cases diagnosed during a defined period, usually a year. Prevalence is the number of people living with the disease at a given point in time.

2 per 100,000

Incidence
New cases diagnosed each year

6 per 100,000

Prevalence
People living with ALS/MND

~140,000

New cases worldwide
Approximately each year

Research has found that incidence is higher in people aged over 50 years. Although classified as a rare disease based on its prevalence, ALS/MND is, in fact, quite common. Approximately 140,000 new cases are diagnosed worldwide each year — about 384 every day.

Genetics and ALS/MND

A small proportion of cases (~10%) are familial (inherited), while the majority of cases (~90%) are still considered sporadic or singleton. However, research continues to reveal genetic associations with ALS/MND.

This may mean that many cases currently considered sporadic also have a genetic contribution. Further research is needed to establish the extent to which genetics contributes to causing and/or moderating ALS/MND.

The Alliance believes that all people diagnosed with ALS/MND should have access to genetic counselling and testing if they choose to.

Living with ALS/MND

The disease affects each individual differently and can have a devastating impact on family, carers, and friends. The rapidly progressive nature of the disease requires constant adaptation to increasing and changing levels of disability, which in turn require increased levels of support.

Find Information and Support in Your Region

For information about ALS/MND in other languages, or to connect with an ALS/MND organization in your region, visit our Member Association directory.

Find a Member Association

Primary Sidebar

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Rob Tison, USA

    Rob Tison, USA

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Lombana, Spain

    Lombana, Spain

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Bob Simonds, USA

    Bob Simonds, USA

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Purningam Jacob, India

    Purningam Jacob, India

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • John Russo, USA

    John Russo, USA
    final3878

  • Conny van der Meijden, Netherlands

    Conny van der Meijden, Netherlands

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Sally Pauls, USA

    Sally Pauls, USA

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Bayley, Australia

    Bayley, Australia

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Paul Launer, USA

    Paul Launer, USA

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Steve

    Steve

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login